{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.59","upperLimit":"41.10","value":"22.6"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"84.19","value":"0"},{"groupId":"OG002","lowerLimit":"6.05","upperLimit":"45.57","value":"21.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"Objective response rate is defined as the proportion of participants who have a tumour response of complete response \\[CR\\] or partial response \\[PR\\] according to the Lugano (2014) response criteria for malignant lymphoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG000","title":"Cohort 1 Non-NK PTCL"},{"description":"Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG001","title":"Cohort 2 NK PTCL"},{"description":"Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG002","title":"Cohort 3 cHL"}],"paramType":"NUMBER","populationDescription":"Response evaluable set included all dosed participants who had measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months)","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}